4//SEC Filing
Shawver Laura 4
Accession 0001415889-25-002955
CIK 0001671858other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:35 PM ET
Size
12.5 KB
Accession
0001415889-25-002955
Insider Transaction Report
Form 4
Shawver Laura
Director
Transactions
- Sale
Common Stock
2025-02-03$12.31/sh−50,000$615,565→ 210,346 total - Exercise/Conversion
Common Stock
2025-02-03$3.15/sh+9,064$28,552→ 219,410 total - Exercise/Conversion
Common Stock
2025-02-03$4.85/sh+40,936$198,540→ 260,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-03−9,064→ 0 totalExercise: $3.15Exp: 2032-05-01→ Common Stock (9,064 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-03−40,936→ 124,064 totalExercise: $4.85Exp: 2032-01-31→ Common Stock (40,936 underlying)
Footnotes (3)
- [F1]The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- [F2]The weighted average sale price for the transaction reported was $12.3113 and the range of prices were between $11.9732 and $12.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.
Documents
Issuer
ARS Pharmaceuticals, Inc.
CIK 0001671858
Entity typeother
Related Parties
1- filerCIK 0001551891
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 4:35 PM ET
- Size
- 12.5 KB